ABC | Volume 110, Nº6, June 2018

Artigo Original Catharina et al Síndrome metabólica na hipertensão Arq Bras Cardiol. 2018; 110(6):514-521 31. ChaudharyK,BuddineniJP,NistalaR,Whaley-ConnellA.Resistanthypertension in the high-riskmetabolic patient. Curr Diab Rep. 2011;11(1):41-6. 32. Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis. 2014 Feb 18;7:75-88. 33. Mule G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensi vepatients:anunholyalliance.WorldJCardiol .2014;6(9):890-907. 34. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566-78. 35. Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622-32. 36. Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, deHaro Moraes C, et al. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press. 2012;21(1):31-8. This is an open-access article distributed under the terms of the Creative Commons Attribution License 521